Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of alpelisib with fulvestrant or letrozole after CDK4/6 inhibitor progression in PIK3CA-mutant HR-positive HER2-negative advanced breast cancer
MOH_2017-06-11_000499Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib, fulvestrant and letrozole in breast cancer (2 arms), sponsored by Novartis. Primary endpoints: Efficacy and Safety. Started Apr 2017; status: completed.
02
Drugs
alpelisibfulvestrantletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-06-11_000499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-11_000499.